The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation introduces two topics to expound on which standout amid a year that proves to be rife with rich, new information.
In this final conversation the Surfers explore the impact they believe ICER’s draft report on resmetirom and obeticholic acid for NASH will have for different stakeholders. The panelists each touch on different perspectives to offer a well-rounded wrap-up.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what’s happening thus far for the Fatty Liver field in 2023. The panelists touch on topics ranging from trials with non-invasive endpoints to guidelines, guidances and cross-specialty screening for liver health.
Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, Donna Cryer and Roger Green share impressions from the regulatory viewpoint.
Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, patient advocates Michael Betel and Tony Villiotti join Louise Campbell and Roger Green to share impressions from a momentous conference.
This week’s conversation series continues on the theme of reviewing NASH-TAG 2023, a watershed moment for Fatty Liver disease. For this wrap-up feature, Amy Articolo and Naim Alkhouri join Jörn Schattenberg and Roger Green to illustrate their enthusiasm coming out of the conference.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Caitlin Schneider (Sonic Incytes) joins Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Jerry Mabary (Chronwell) joins Roger Green to explore questions around biopsy, patient centricity, the role of digital tools and combination therapy
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Pamela Danagher (Terns Pharma) joins Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. Respectively, Pamela Danagher (Terns Pharma), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.
